Stevanato Group S.p.A. (STVN)

Market Cap	4.92B -19.9%
Revenue (ttm)	1.39B +7.0%
Net Income	162.98M +12.6%
EPS	0.59 +11.1%
Shares Out	273.00M
PE Ratio	30.63
Forward PE	24.40
Dividend	$0.06 (0.35%)
Ex-Dividend Date	Jun 5, 2025

Volume	218,678
Open	17.84
Previous Close	17.85
Day's Range	17.84 - 18.44
52-Week Range	12.89 - 28.00
Beta	0.75
Analysts	Buy
Price Target	28.86 (+60.24%)
Earnings Date	May 7, 2026

About STVN

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injector...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jul 16, 2021
• Employees: 6,010
• Stock Exchange: NYSE
• Ticker Symbol: STVN
• Website: https://www.stevanatogroup.com

Financial Performance

In 2025, Stevanato Group's revenue was 1.19 billion, an increase of 7.45% compared to the previous year's 1.10 billion. Earnings were 139.84 million, an increase of 18.73%.

Financial numbers in EUR

Analyst Summary

According to 10 analysts, the average rating for STVN stock is "Buy." The 12-month stock price target is $28.86, which is an increase of 60.24% from the latest price.

Price Target

$28.86

(60.24% upside)

Analyst Consensus: Buy